Market Intelligence, Clinical Progress, and High-Purity Reagents for Oncology and Fibrosis Therapeutic Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for EPB41L5 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | EPB41L5 Recombinant Protein (FERM Domain / Full Length) High purity (>95%), Endotoxin controlled. Sequence Verified. Suitable for biophysical screening. |
View EPB41L5 Products |
| Gene Delivery | EPB41L5 Promise-ORF / Lentivirus Full-length ORF for stable cell line construction and EMT assay development. |
View EPB41L5 Products |
| Benchmark Ab | Anti-EPB41L5 Recombinant Antibody High-affinity positive control for Western Blot, IHC, and immunoprecipitation. |
View EPB41L5 Products |
| Validator | EPB41L5 siRNA Set Target-specific knockdown verification in functional cell-based assays. |
View EPB41L5 Products |
| Related Target A | YAP1 Downstream effector in the Hippo pathway regulated by EPB41L5-induced cell tension. |
View YAP1 Products |
| Related Target B | TGFB1 Upstream driver of EMT that significantly upregulates EPB41L5 expression. |
View TGFB1 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Intracellular Adaptor Complexity | Eukaryotic HEK293-expressed proteins preserve native folding of the crucial FERM domain. |
| High-Throughput Biophysical Screening | Highly stable, monomeric recombinant proteins verified by SEC-HPLC for SPR/MST assays. |
| Lack of Controls | Clinical-grade benchmark antibodies and validated siRNA sequences included for assay baseline setup. |
| False Positives in EMT Profiling | Sequence-verified ORF lentiviruses ensure stable and reproducible phenotypic transitions. |
Live EPB41L5 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for EPB41L5 therapeutics is intensifying, with major players shifting focus from traditional extracellular targets to intracellular adaptors regulating the epithelial-mesenchymal transition (EMT). As first-generation broad-spectrum kinase inhibitors face resistance, the next wave of R&D is targeting the EPB41L5-p120-catenin-E-cadherin axis to directly arrest tumor metastasis and fibrotic progression.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule Inhibitors | Academic Consortia, Biotech Startups | Triple-Negative Breast Cancer (TNBC), Gastric Cancer | Biophysical binding assays (Requires high-purity FERM-domain EPB41L5 protein) |
| RNA Therapeutics (siRNA/ASO) | RNAi Specialists | Pulmonary Fibrosis, Hepatic Fibrosis | Target knockdown validation (Requires validated EPB41L5 siRNA and Lentiviral overexpressing controls) |
| Combination Therapies (with EGFRi) | Oncology Biopharma | EGFR-Mutant Resistant NSCLC | Co-immunoprecipitation and Western Blot screening (Requires sequence-verified EPB41L5 antibodies) |